Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 107

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis

Gu, Junlian, Wang, Shudong, Guo, Hua, Tan, Yi, Liang, Yaqin, Feng, Anyun, Liu, Qiuju, Damodaran, Chendil, Zhang, Zhiguo, Keller, Bradley B., Zhang, Chi, Cai, Lu·2018·Cell Death & Disease

Abstract

Elevated tumor suppressor p53 expression has been associated with heart diseases, including the diabetic heart. However, its precise role in the pathogenesis of diabetic cardiomyopathy (DCM) remains unclear. We hypothesized that the development of DCM is attributed to up-regulated p53-mediated both early cardiac cell death and persistent cell senescence, glycolytic and angiogenetic dysfunctions. The present study investigated the effect of p53 inhibition with its specific inhibitor pifithrin-α (PFT-α) on the pathogenesis of DCM and its associated mechanisms. Type 1 diabetes was induced with multiple low doses of streptozotocin. Both hyperglycemic and age-matched control mice were treated with and without PFT-α five times a week for 2 months and then sacrificed at 3 and 6 months post-diabetes. Treatment with PFT-α significantly prevented the progression of diabetes-induced cardiac remodeling and dysfunction (i.e., DCM). Mechanistically, the inhibition of p53 prevented the cardiac apoptosis during early-stage diabetes (0.5 month), attenuated diabetes-induced cell senescence (3 and 6 months), and improved both glycolytic and angiogenic defects by increasing hypoxia-induced factor (HIF)-1α protein stability and upregulating HIF-1α transcription of specific target genes at 3 and 6 months after diabetes. Therefore, the targeted inhibition of p53 in diabetic individuals may provide a novel approach for the prevention of DCM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-017-0093-5

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 38

  1. Shaw, J. E., Sicree, R. A. & Zimmet, P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes. Res. Clin. Pract. 87, 4–14 (2010). · DOI · Paper page
  2. Boudina, S. & Abel, E. D. Diabetic cardiomyopathy revisited. Circulation. 115, 3213–3223 (2007). · DOI · Paper page
  3. Monkemann, H. et al. Early molecular events in the development of the diabetic cardiomyopathy. Amino. Acids. 23, 331–336 (2002). · DOI
  4. Cai, L. et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 51, 1938–1948 (2002). · DOI · Paper page
  5. Cai, L. & Kang, Y. J. Cell death and diabetic cardiomyopathy. Cardiovasc. Toxicol. 3, 219–228 (2003). · DOI · Paper page
  6. van de Weijer, T., Schrauwen-Hinderling, V. B. & Schrauwen, P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc. Res. 92, 10–18 (2011). · DOI · Paper page
  7. Kajstura, J. et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes. 50, 1414–1424 (2001). · DOI · Paper page
  8. Yoshida, Y. et al. p53-Induced inflammation exacerbates cardiac dysfunction during pressure overload. J. Mol. Cell. Cardiol. 85, 183–198 (2015). · DOI
  9. Zhang, Y. et al. Inhibition of p53 after acute myocardial infarction: reduction of apoptosis is counteracted by disturbed scar formation and cardiac rupture. J. Mol. Cell. Cardiol. 50, 471–478 (2011). · DOI
  10. Nakamura, H. et al. p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation. Circ Heart Fail 5, 106–115 (2012). · DOI · Paper page
  11. Wold, L. E. & Ren, J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem. Biophys. Res. Commun. 318, 1066–1071 (2004). · DOI
  12. Raza, H. & John, A. Streptozotocin-induced cytotoxicity, oxidative stress and mitochondrial dysfunction in human hepatoma HepG2 cells. Int J Mol Sci 13, 5751–5767 (2012). · DOI
  13. Schwartzenberg-Bar-Yoseph, F., Armoni, M. & Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer. Res. 64, 2627–2633 (2004). · DOI · Paper page
  14. Jiang, P. et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell. Biol. 13, 310–316 (2011). · DOI · Paper page
  15. Bai, Y. et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J. Mol. Cell. Cardiol. 57, 82–95 (2013). · DOI · Paper page
  16. Cai, L. et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes. 54, 1829–1837 (2005). · DOI · Paper page
  17. Martinou, J. C. & Youle, R. J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell. 21, 92–101 (2011). · DOI · Paper page
  18. Lall, R. et al. Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response. Cell. Death. Differ. 21, 836–844 (2014). · DOI
  19. Kainulainen, H. et al. In vivo glucose uptake and glucose transporter proteins GLUT1 and GLUT4 in heart and various types of skeletal muscle from streptozotocin-diabetic rats. Biochim. Biophys. Acta. 1225, 275–282 (1994). · DOI
  20. Xue, W. et al. Cardiac-specific overexpression of HIF-1{alpha} prevents deterioration of glycolytic pathway and cardiac remodeling in streptozotocin-induced diabetic mice. Am. J. Pathol. 177, 97–105 (2010). · DOI
  21. Amelio, I. et al. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1alpha degradation. Proc Natl Acad Sci U S A 112, 226–231 (2015). · DOI
  22. Harvey, P. A. & Leinwand, L. A. The cell biology of disease: cellular mechanisms of cardiomyopathy. J. Cell. Biol. 194, 355–365 (2011). · DOI · Paper page
  23. Correia-Melo, C., Hewitt, G. & Passos, J. F. Telomeres, oxidative stress and inflammatory factors: partners in cellular senescence? Longev Healthspan 3, 1 (2014). · DOI · Paper page
  24. Natarajan, R. et al. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ. Res. 98, 133–140 (2006). · DOI · Paper page
  25. Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 446, 444–448 (2007). · DOI · Paper page
  26. Yoon, Y. S. et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation. 111, 2073–2085 (2005). · DOI · Paper page
  27. Schneider-Stock, R. et al. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J. Pharmacol. Exp. Ther. 312, 525–536 (2005). · DOI
  28. Culmsee, C. et al. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J. Neurosci. 23, 8586–8595 (2003). · DOI
  29. Zhang, J. et al. Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin. Sci. 130, 625–641 (2016). · DOI · Paper page
  30. Hoshino, A. et al. Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic beta-cell function in diabetes. Proc Natl Acad Sci U S A 111, 3116–3121 (2014). · DOI · Paper page
  31. Derdak, Z. et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J. Hepatol. 58, 785–791 (2013). · DOI · Paper page
  32. Shimizu, I. et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell. Metab. 15, 51–64 (2012). · DOI · Paper page
  33. Gu, J. et al. Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy. Diabetes. 66, 529–542 (2017). · DOI · Paper page
  34. Tan, Y. et al. Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. J. Am. Coll. Cardiol. 59, 1477–1486 (2012). · DOI
  35. Luo, J. et al. Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure. Am. J. Physiol. Heart. Circ. Physiol. 293, H3673–H3684 (2007). · DOI
  36. Gu, J. et al. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur. J. Cancer. 50, 1184–1194 (2014). · DOI
  37. Zhang, Z. et al. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. J. Mol. Cell. Cardiol. 77, 42–52 (2014). · DOI · Paper page
  38. Wang, S. et al. Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/p38 MAPK pathway. J. Cell. Mol. Med. 21, 1182–1192 (2017). · DOI

Cited by

See all 107

Metadata

Authors
Gu, J., Wang, S., Guo, H., Tan, Y., Liang, Y., Feng, A., Liu, Q., Damodaran, C., Zhang, Z., Keller, B. B., Zhang, C., & Cai, L.
Venue
Cell Death & Disease
Published
2018-01-23
Volume
9
Issue
2
ISSN
2041-4889
Cited by
107
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. https://app.cochat.ai/papers/10.1038/s41419-017-0093-5
The paper
Gu, J., Wang, S., Guo, H., Tan, Y., Liang, Y., Feng, A., Liu, Q., Damodaran, C., Zhang, Z., Keller, B. B., Zhang, C., & Cai, L. (2018). Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death & Disease. https://doi.org/10.1038/s41419-017-0093-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.